Comunicado oficial | Fallecimiento de nuestro anterior Vicedirector Científico, Pedro Valdivielso Felices 

 

 

From the Institute we would like to express, with great sadness, the sad news of the death of Pedro Valdivielso Felices, who was our Vice Scientific Director from 2017 to 2022, and President of the Training Commission from the beginning until 2023. In his enormous career as a researcher, also highlights the leadership of the research group 'Arteriosclerosis, vascular prevention, metabolism and neurological diseases'. 

As a result of all his scientific and medical knowledge, his legacy has been directly transferred to clinical practice, with benefits for the health and quality of life of patients, especially in relation to Rare Diseases to which he has dedicated a large part of his work, such as pseudoxanthoma elasticum, among others.

He has been linked to the Virgen de la Victoria University Hospital as a specialist in Internal Medicine, and to the University of Malaga, where he was Professor of the Department of Medicine and Dermatology in the Faculty of Medicine. A man of a friendly and friendly nature, his involvement with teaching was also reflected in our Institute, since, over the years, he has developed, with affection, professionalism and enormous involvement, training plans that have served as a basis and support for the present and future of our professionals, leaving an indelible memory for future

 

On behalf of the entire scientific community.

Rest in Peace.

 

Raúl J. Andrade Bellido, es Investigador Responsable del grupo consolidado ‘Hepatogastroenterología, Farmacología y Terapéutica Clínica Traslacional’ de IBIMA Plataforma BIONAND, Catedrático y Director del Departamento de Medicina en la Facultad de Medicina de la Universidad de Málaga, Jefe de Servicio Aparato Digestivo del Hospital Universitario Virgen de la Victoria en Málaga. Además,  es el Responsable del Grupo Español de Hepatopatias asociadas a medicamentos (Spanish DILI Registry), el Coordinador de la Red Ibero-Americana de Hepatopatías asociadas a medicamentos (SLATINDILI) y también del Registro europeo de Hepatopatías asociadas a Medicamentos (Pro-Euro DILI Registry). Chair de la COST Action CA17112 – Prospective European Drug-Induced Liver Injury Network (PRO-EURO DILI NET) y del EASL DHILI Consortium. Horizonte2020. Framework Programme (European Union).

Noticias Relacionadas